Prepared Statement by U.S. Senator Chuck Grassley of Iowa
Co-Chair, Senate Caucus on International Narcotics Control and Ranking
Member, Senate Judiciary Committee
Hearing
on the Office of National Drug Control Policy’s 2022 Drug Control Strategy
Wednesday,
June 15, 2022
Today's hearing will examine the Office
of the National Drug Control Policy's coordination of national drug control
efforts, and preliminary reviews of the Drug Control Strategy by the government
watchdog, GAO.
ONDCP was created to serve as our
nation's leader in combatting drugs. Since its inception in 1989, the threats
posed by drugs have evolved. But the mission of ONDCP and of this Drug Caucus
remains the same: to save lives.
This hearing comes at a critical
juncture for our nation. We’re in the middle of the most destructive and
challenging drug environment this country has ever seen.
By now, we’ve all seen the numbers. The
Center for Disease Control and Prevention reported that nearly 108,000
Americans died last year from a drug overdose. This is staggering. This is
unacceptable.
Iowa’s no stranger to the drug crisis.
Our towns and communities have been hit hard by the impact of lethal drugs.
This includes meth, fentanyl and now the spread of deadly
counterfeit pills.
Fentanyl overdoses have become the number
one cause of death among US adults ages 18-45. Overdose deaths from
methamphetamine have tripled in recent years according to the National
Institutes of Health.
Common sense tells us that we need ONDCP
to lead efforts and steer a national strategy that makes it harder to obtain
and use fentanyl and its analogues, meth, synthetic opioids and other drugs.
We need to be focused on stopping the
spread of these drugs. But I think ONDCP's 2022 Strategy could do better at
that.
The strategy doesn’t put enough emphasis
on
scheduling fentanyl analogues permanently. Also, tackling counterfeit
pills laced with fentanyl and meth is hardly even mentioned in the strategy.
I’m concerned that the strategy's emphasis on harm reduction could allow for an
even greater use of drugs. I’m also concerned that the strategy notes that ONDCP
will take a review of where mandatory minimum sentences for drug offenses
should be eliminated.
This guiding document sets the tone for
how our nation perceives drug policy and calls our federal and state partners
to action. I’m worried that making drugs more accessible is what this administration
calls "drug control.”
I’d prefer if the strategy focused on
the most lethal drugs facing us. We need to make it harder to get and use drugs
and find areas where we can get real work done. I have a few ideas on that.
The permanent scheduling of all fentanyl
related substances is a start. ONDCP has supported class wide scheduling of
fentanyl analogues, and I hope that’s still the case.
Second, the
Methamphetamine
Response Act that I introduced with Senator
Feinstein was signed into law, and I look forward to working with ONDCP on its
implementation.
Also, Congress can continue supporting
prevention efforts, like educating parents and children to stop access and use
of drugs.
But there’s more work to be done. I look
forward to hearing from ONDCP Director Gupta today and discussing how we can
work together to turn the tide.
Thank you again to our witnesses for
being here today, and I look forward to your testimony.
-30-